Company Profile
Aprea Therapeutics Stock Price, News & Analysis
- Ticker:
- APRE
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Aprea Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Stock performance
0.83 USD (+4.33%)
Close
Last updated: June 23, 2026 at 00:00
10.25M USD
Market cap
Why the stock is moving
APRE is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Aprea Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Aprea Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Aprea Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Aprea Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Source: Aprea Therapeutics
- 03
- 04
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
Source: Aprea Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Aprea Therapeutics (APRE)?
Aprea Therapeutics (APRE) most recently closed at 0.83 USD, a +4.33% move versus the previous session.
What is the market cap of Aprea Therapeutics (APRE)?
Aprea Therapeutics currently has a market capitalization of 10.25M USD on BioPharmSignal.
What does Aprea Therapeutics do?
Aprea Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is APRE stock listed?
Aprea Therapeutics (APRE) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Aprea Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts., Biotechnology.
What is Aprea?
Aprea Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Aprea Therapeutics targeting with Aprea?
Aprea Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Therapeutics?
Aprea Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.